Are there clinical implications of racial differences in HbA1c? A difference, to be a difference, must make a difference

Diabetes Care

Volumn 39, Issue 8, 2016, Pages 1462-1467

  Selvin, Elizabeth ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AFRICAN AMERICAN; AFRICAN BRAZILIAN; ARTICLE; BLACK PERSON; CAUCASIAN; CAUSE OF DEATH; DIABETES MELLITUS; ERYTHROCYTE METABOLISM; GENETIC DIFFERENCE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INUIT; MEXICAN AMERICAN; PROGNOSIS; RACE DIFFERENCE; RISK REDUCTION; SOUTH ASIAN; VALIDITY; AGED; ATHEROSCLEROSIS; BLOOD; DECISION MAKING; ETHNOLOGY; METABOLISM; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY; RISK FACTOR; SOCIOECONOMICS;

AFRICAN AMERICANS; AGED; ATHEROSCLEROSIS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DECISION MAKING; DIABETES MELLITUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MIDDLE AGED; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SOCIOECONOMIC FACTORS; TRIGLYCERIDES;

EID: 84980390207     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0042     Document Type: Article

References (73)

1. The International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32:1327-1334
2. American Diabetes Association. Standards of medical care in diabetesd-2010. Diabetes Care 2010; 33(Suppl. 1):S11-S61
3. World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation [Internet], 2011. World Health Organization. Available from http://www.who.int/diabetes/publications/report-hba1c-2011.pdf. Accessed 26 May 2016
4. International Diabetes Federation Clinical Guidelines Task Force. Global guideline for type 2 diabetes [Internet], 2012. International Diabetes Federation. Available from http://www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf. Accessed 26 May 2016
5. Sacks DB Hemoglobin A1c in diabetes: panacea or pointless? Diabetes 2013; 62:41-43
6. Jack L, Jack NH, Hayes SC. Social determinants of health in minority populations: a call for multidisciplinary approaches to eliminate diabetes-related health disparities. Diabetes Spectr 2012; 25:9-13
7. Agardh E, Allebeck P, Hallqvist J, Moradi T, Sidorchuk A. Type 2 diabetes incidence and socio economic position: a systematic review and meta-analysis. Int J Epidemiol 2011; 40:804-818
8. Brancati FL, Kao WHL, Folsom AR, Watson RL, Szklo M. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA 2000; 283:2253-2259
9. Bower JK, Brancati FL, Selvin E. No ethnic differences in the association of glycated hemoglobin with retinopathy: the National Health and Nutrition Examination Survey 2005-2008. Diabetes Care 2013; 36:569-573
10. Tsugawa Y, Mukamal KJ, Davis RB, Taylor WC, Wee CC. Should the hemoglobin A1c diagnostic cutoff differ between blacks and whites? A cross-sectional study. Ann Intern Med 2012; 157:153-159
11. Crews DC, Pfaff T, Powe NR. Socioeconomic factors and racial disparities in kidney disease outcomes. Semin Nephrol 2013; 33:468-475
12. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110:738-743
13. Gregg EW, Sorlie P, Paulose-Ram R, et al.; 1999-2000 National Health and Nutrition Examination Survey. Prevalence of lower-extremity disease inthe U.S. adult population.540 years of age with and without diabetes: 1999-2000 National Health and Nutrition Examination Survey. Diabetes Care 2004; 27:1591-1597
14. Goodney PPDN, Goodman DC, Bronner KK. Variation in the Care of Surgical Conditions: Diabetes and Peripheral Arterial Disease: A Dartmouth Atlas of Health Care Series, 2014. Available from http://www.dartmouthatlas.org/downloads/reports/Diabetes-report-10-14-14.pdf. Accessed 26 May 2016
15. Tarver-Carr ME, Powe NR, Eberhardt MS, et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J Am Soc Nephrol 2002; 13:2363-2370
16. Parsa A, Kao WHL, Xie D, et al.; AASK Study Investigators; CRIC Study Investigators. APOL1risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369:2183-2196
17. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999; 22:403-408
18. Selvin E, Rawlings AM, Bergenstal RM, Coresh J, Brancati FL. No racial differences in the association of glycated hemoglobin with kidney disease and cardiovascular outcomes. Diabetes Care 2013; 36:2995-3001
19. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362:800-811
20. Kirk JK, D'Agostino RB Jr, Bell RA, et al. Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a metaanalysis. Diabetes Care 2006; 29:2130-2136
21. Saaddine JB, Fagot-Campagna A, Rolka D, et al. Distribution of HbA(1c) levels for children and young adults in the U.S.: Third National Health and Nutrition Examination Survey. Diabetes Care 2002; 25:1326-1330
22. Menke A, Rust KF, Savage PJ, Cowie CC. Hemoglobin A1c, fasting plasma glucose, and 2-hour plasma glucose distributions in U.S. population subgroups: NHANES 2005-2010. Ann Epidemiol 2014; 24:83-89
23. Shipman KE, Jawad M, Sullivan KM, Ford C, Gama R. Ethnic/racial determinants of glycemic markers in a UK sample. Acta Diabetol 2015; 52: 687-692
24. de Miranda VA, Cruz Filho RA, de Oliveira TS, et al. Racial differences in HbA1c: a crosssectional analysis of a Brazilian public primary care population. Prim Care Diabetes 2013; 7:135-141
25. Jørgensen ME, Bjerregaard P, Borch Johnsen K, Witte D. New diagnostic criteria for diabetes: is the change from glucose to HbA1c possible in all populations? J Clin Endocrinol Metab 2010; 95:E333-E336
26. Inzucchi SE Clinical practice. Diagnosis of diabetes. N Engl J Med 2012; 367:542-550
27. Sacks DB A1C versus glucose testing: a comparison. Diabetes Care 2011; 34:518-523
28. Davidson MB Diagnosing diabetes with glucose criteria: worshiping a false God. Diabetes Care 2011; 34:524-526
29. American Diabetes Association. Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetesd2016. Diabetes Care 2016; 39(Suppl. 1):S13-S22
30. 1(c) as a diagnostic test: the ethnic conundrum. Nat Rev Endocrinol 2010; 6:589-593
31. Herman WH, Ma Y, Uwaifo G, et al.; Diabetes Prevention Program Research Group. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007; 30:2453-2457
32. Bunn HF, Haney DN, Kamin S, Gabbay KH, Gallop PM. The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. J Clin Invest 1976; 57:1652-1659
33. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31:1473-1478
34. Koenig RJ, Peterson CM, Kilo C, Cerami A, Williamson JR. Hemoglobin A1c as an indicator of the degree of glucose intolerance in diabetes. Diabetes 1976; 25:230-232
35. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984; 310:341-346
36. Mortensen HB, Christophersen C. Glucosylation of human haemoglobin a in red blood cells studied in vitro. Kinetics of the formation and dissociation of haemoglobin A1c. Clin Chim Acta 1983; 134:317-326
37. Franco RS The measurement and importance of red cell survival. Am J Hematol 2009; 84:109-114
38. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001; 47:153-163
39. Parrinello CM, Sharrett AR, Maruthur NM, Bergenstal RM, Grams ME, Coresh J, et al. Racial differences in and prognostic value of biomarkers of hyperglycemia. Diabetes Care. 17 December 2015 [Epub ahead of print]
40. Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med 2011; 154:303-309
41. Kohzuma T, Yamamoto T, Uematsu Y, Shihabi ZK, Freedman BI. Basic performance of an enzymatic method for glycated albumin and reference range determination. J Diabetes Sci Technol 2011; 5:1455-1462
42. Shafi T, Sozio SM, Plantinga LC, et al. Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. Diabetes Care 2013; 36:1522-1533
43. Maruthur NM, Kao WH, Clark JM, et al. Does genetic ancestry explain higher values of glycated hemoglobin in African Americans? Diabetes 2011; 60:2434-2438
44. 1(C) levels via glycemic and nonglycemic pathways. Diabetes 2010; 59: 3229-3239
45. Soranzo N. Genetic determinants of variability in glycated hemoglobin (HbA(1c)) in humans: review of recent progress and prospects for use in diabetes care. Curr Diab Rep 2011; 11:562-569
46. An P, Miljkovic I, Thyagarajan B, et al. Genome-wide association study identifies common loci influencing circulating glycated hemoglobin (HbA1c) levels in non-diabetic subjects: the Long Life Family Study (LLFS). Metabolism 2014; 63:461-468
47. Havranek EP, Mujahid MS, Barr DA, et al.; American Heart Association Council on Quality of Care and Outcomes Research, Council on Epidemiology and Prevention, Council on Cardiovascular and Stroke Nursing, Council on Lifestyle and Cardiometabolic Health, and Stroke Council. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2015; 132:873-898
48. Collins FS What we do and don't know about 'race', 'ethnicity', genetics and health at the dawn of the genome era. Nat Genet 2004; 36(Suppl.):S13-S15
49. Heianza Y, Hara S, Arase Y, et al. HbA1c 5.7-6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet 2011; 378:147-155
50. Droumaguet C, Balkau B, Simon D, et al.; DESIR Study Group. Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2006; 29:1619-1625
51. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141:413-420
52. Matsushita K, Blecker S, Pazin-Filho A, et al. The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diabetes 2010; 59:2020-2026
53. Selvin E, Ning Y, Steffes MW, et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes 2011; 60:298-305
54. Di Angelantonio E, Gao P, Khan H, et al.; Emerging Risk Factors Collaboration. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA 2014; 311:1225-1233
55. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K; DETECT-2 Collaboration Writing Group. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 2011; 34:145-150
56. Cheng YJ, Gregg EW, Geiss LS, et al. Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds. Diabetes Care 2009; 32:2027-2032
57. Wong TY, Liew G, Tapp RJ, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet 2008; 371:736-743
58. Jeganathan VS, Cheung N, Tay WT, Wang JJ, Mitchell P, WongTY. Prevalence and risk factors of retinopathy in an Asian population without diabetes: the Singapore Malay Eye Study. Arch Ophthalmol 2010; 128:40-45
59. Tapp RJ, Zimmet PZ, Harper CA, et al.; AusDiab Study Group. Diagnostic thresholds for diabetes: the association of retinopathy and albuminuria with glycaemia. Diabetes Res Clin Pract 2006; 73:315-321
60. McCance DR, Hanson RL, Charles MA, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 1994; 308:1323-1328
61. Engelgau MM, Thompson TJ, Herman WH, et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 1997; 20:785-791
62. Park YM, Ko SH, Lee JM, et al.; Committee of Clinical Practice Guideline, Korean Diabetes Association. Glycaemic and haemoglobin A1c thresholds for detecting diabetic retinopathy: the fifth Korea National Health and Nutrition Examination Survey (2011). Diabetes Res Clin Pract 2014; 104:435-442
63. Xin Z, Yuan MX, Li HX, et al. Evaluation for fasting and 2-hour glucose and HbA1c for diagnosing diabetes based on prevalence of retinopathy in a Chinese population. PLoS One 2012; 7: e40610
64. Tsugawa Y, Takahashi O, Meigs JB, et al. New diabetes diagnostic threshold of hemoglobin A(1c) and the 3-year incidence of retinopathy. Diabetes 2012; 61:3280-3284
65. Fukushima S, Nakagami T, Suto C, Hirose A, Uchigata Y. Prevalence of retinopathy and its risk factors in a Japanese population. J Diabetes Investig 2013; 4:349-354
66. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559
67. Selvin E, Coresh J, Shahar E, Zhang L, Steffes M, Sharrett AR. Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Lancet Neurol 2005; 4:821-826
68. Saydah S, Tao M, Imperatore G, Gregg E. GHb level and subsequent mortality among adults in the U.S. Diabetes Care 2009; 32:1440-1446
69. Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR. HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities Study. Diabetes Care 2006; 29: 877-882
70. Sabanayagam C, Khoo EY, Lye WK, et al. Diagnosis of diabetes mellitus using HbA1c in Asians: relationship between HbA1c and retinopathy in a multiethnic Asian population. J Clin Endocrinol Metab 2015; 100:689-696
71. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA)and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35:1364-1379
72. National Guideline Clearinghouse. VA/DoD clinical practice guideline for the management of diabetes mellitus [Internet], 2012. Rockville, MD, Agency for Healthcare Research and Quality (AHRQ). Available from http://www.healthquality.va.gov/guidelines/CD/diabetes/AboutDM.asp. Accessed 26 May 2016
73. American Diabetes Association. Strategies for improving care. Sec. 1. In Standards of Medical Care in Diabetesd 2016. Diabetes Care 2016; 39(Suppl. 1):S6-S12